Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...
Reexamination Certificate
2006-11-14
2006-11-14
Campell, Bruce R. (Department: 1648)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
C435S005000, C435S006120, C424S184100
Reexamination Certificate
active
07135278
ABSTRACT:
The present invention relates to a method of screening for a host cell gene products which are useful as therapeutics for an infective disease. This method comprises identifying genes which are differentially expressed in infected cells, and screening the differentially expressed gene products for immunogenicity.
REFERENCES:
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5525471 (1996-06-01), Zeng
patent: 5700644 (1997-12-01), Gould et al.
patent: 5721351 (1998-02-01), Levinson
patent: 5827658 (1998-10-01), Liang
patent: 5879892 (1999-03-01), Van Baren et al.
patent: 6004755 (1999-12-01), Wang
patent: 6033860 (2000-03-01), Lockhart et al.
patent: 6045996 (2000-04-01), Cronin et al.
patent: 6060240 (2000-05-01), Kamb et al.
patent: 6060288 (2000-05-01), Adams et al.
patent: 6312909 (2001-11-01), Shyjan
patent: 6399328 (2002-06-01), Vournakis et al.
patent: 6706477 (2004-03-01), Zauderer
patent: 6800442 (2004-10-01), Zauderer
patent: 6872518 (2005-03-01), Zauderer
patent: 2002/0155447 (2002-10-01), Zauderer et al.
patent: 2003/0022157 (2003-01-01), Zauderer et al.
patent: 2003/0194696 (2003-10-01), Zauderer et al.
patent: 2004/0063907 (2004-04-01), Zauderer et al.
patent: WO 98/46638 (1998-10-01), None
patent: WO 02/27027 (2002-04-01), None
patent: WO 02/31117 (2002-04-01), None
Tanaka et al., “Genome-wide Expression Profiling of Mid-gestation Placenta and Embryo using a 15,000 Mouse Developmental cDNA Library,” Proceedings of the National Academy of Sciences, vol. 97, pp. 9127-9132.
Hernández et al., Proceedings of the National Academy of Sciences USA, vol. 99 No. 19, pp. 12275-12280 ( Sep. 2002).
Herberts et al., Human Immunology, 64: 44-55 (2003- submitted by Applicant in the Response of Oct. 2003).
Hickman et al., Journal of Immunology, 171: 22-26 (2003- submitted by Applicant in the Response of Oct. 2003).
An, D.S., et al., “High-Efficiency Transduction of Human Lymphoid Progenitor Cells and Expression in Differentiated T Cells,”J. Virol. 71:1397-1404, American Society for Microbiology (1997).
Bennink, J.R., and Yewdell, J.W., “Recombinant Vaccinia Viruses as Vectors for Studying T Lymphocyte Specificity and Function,”Curr. Top. Microbiol. Immunol. 163:153-184, Springer-Verlag (1990).
Bloom, M.B., et al., “Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma,”J. Exp. Med. 185:453-459, Rockefeller University Press (1997).
Blum-Tirouvanziam, U., et al., “Localization of HLA-A2.1-Restricted T Cell Epitopes in the Circumsporozoite Protein ofPlasmodium falciparum,” J. Immunol. 154:3922-3931, The American Association of Immunologists (1995).
Boël, P., et al., “BAGE: a New Gene Encoding an Antigen Recognized on Human Melanomas by Cytolytic T Lymphocytes,”Immunity 2:167-175, Cell Press (1995).
Bowtell, D.D.L., “Options available—from start to finish—for obtaining expression data by microarray,”Nat. Genet.(Supplement) 21:25-32, Nature Publishing Co. (Jan. 1999).
Brichard, V., et al., “The Tyrosinase Gene Codes for an Antigen Recognized by Autologous Cytolytic T Lymphocytes on HLA-A2 Melanomas,”J. Exp. Med. 178:489-495, Rockefeller University Press (1993).
Butera, S.T., et al., “Human Immunodeficiency Virus Type 1 RNA Expression by Four Chronically Infected Cell Lines Indicates Multiple Mechanisms of Latency,”J. Virol. 68:2726-2730, American Society for Microbiology (1994).
Cannon, P., et al., “Analysis of Tat Function in Human Immunodeficiency Virus Type 1-Infected Low-Level-Expression Cell Lines U1 and ACH-2,”J. Virol. 68:1993-1997, American Society for Microbiology (1994).
Chaux, P., et al., “Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced withMAGE-A1,” J. Immunol. 163:2928-2936, The American Association of Immunologists (Sep. 1999).
Cheung, V.G., et al., “Making and reading microarrays,”Nat. Genet. 21(Supplement):15-19, Nature Publishing Co. (Jan. 1999).
DeRisi, J., et al., “Use of a cDNA microarray to analyse gene expression patterns in human cancer,”Nat. Genet. 14:457-460, Nature Publishing Co. (1996).
Duggan, D.J., et al., “Expression profiling using cDNA microarrays,”Nat. Genet. 21(Supplement):10-14, Nature Publishing Co. (Jan. 1999).
Eisen, M.B., and Brown, P.O., “DNA Arrays for Analysis of Gene Expression,”Methods Enzymol. 303:179-205, Academic Press (Jun. 1999).
Gaugler, B., et al., “Human Gene MAGE-3 Codes for an Antigen Recognized on a Melanoma by Autologous Cytolytic T Lymphocytes,”J. Exp. Med. 179:921-930, The Rockefeller University Press (1994).
Geiss, G.K., et al., “Large-Scale Monitoring of Host Cell Gene Expression during HIV-1 Infection Using cDNA Microarrays,”Virology 266:8-16, Academic Press (Jan. 2000).
Kawakami, Y., et al., “Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor,”Proc. Natl. Acad. Sci. USA 91:3515-3519, National Academy of Sciences (1994).
Kawakami, Y., et al., “Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated within vivotumor rejection,”Proc. Natl. Acad. Sci. USA 91:6458-6462, National Academy of Sciences (1994).
Liang, P., and Pardee, A.B., “Differential Display of Eukaryotic Messenger RNA by Means of the Polymerase Chain Reaction,”Science 257:967-971, American Association for the Advancement of Science (1992).
Linsley, P.S., “Immunosuppression in Vivo by a Soluble Form of the CTLA-4 T Cell Activation Molecule,”Science 257:792-795, American Association for the Advancement of Science (1992).
Lipshutz, R.J., et al., “High density synthetic oligonucleotide arrays,”Nat. Genet. 21(Supplement):20-24, Nature Publishing Co. (Jan. 1999).
Lisitsyn, N., et al., “Cloning the Differences Between Two Complex Genomes,”Science 259:946-951, American Association for the Advancement of Science (1993).
Merchlinsky, M., and Moss, B., “Introduction of Foreign DNA into the Vaccinia Virus Genome byin VitroLigation: Recombination-Independent Selectable Cloning Vectors,”Virology 190:522-526, Academic Press (1992).
Merchlinsky, M., et al., “Construction and Characterization of Vaccinia Direct Ligation Vectors,”Virology 238:444-451, Academic Press (1997).
Parker, K.C., et al., “Scheme for Ranking Potential HLA-A2 Binding Peptides Based on Independent Binding of Individual Peptide Side-Chains,”J. Immunol. 152:163-175, The American Association of Immunologists (1994).
Planelles, V., et al., “Fate of the Human Immunodeficiency Virus Type 1 Provirus in Infected Cells: a role forvpr,” J. Virol. 69:5883-5889, American Society for Microbiology (1995).
Reddy, A., et al., “A Monocyte Conditioned Medium Is More Effective Than Defined Cytokines in Mediating the Terminal Maturation of Human Dendritic Cells,”Blood 90:3640-3646, The American Society of Hematology (1997).
Ressing, M.E., et al., “Human CTL Epitopes Encoded by Human Papillomavirus Type 16 E6 and E7 Identified Through In Vivo and In Vitro Immunogenicity Studies of HLA-A*0201-Binding Peptides,”J. Immunol. 154:5934-5943, The American Association of Immunologists (1995).
Rosenblatt, J.D., et al., “Transactivation of Cellular Genes by Human Retroviruses,”Curr. Top. Microbiol. Immunol. 193:25-49, Springer-Verlag (1995).
Scheiflinger, F., et al., “Construction of chimeric vaccinia viruses by molecular cloning and packaging,”Proc. Natl. Acad. Sci. USA 89:9977-9981, National Academy of Sciences (1992).
Schena, M., et al., “Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray,”Science 270:467-470, American Association for the Advancement of Science (1995).
Schena, M., et al.
Campell Bruce R.
Lucas Zachariah
Sterne Kessler Goldstein & Fox P.L.L.C.
University of Rochester
LandOfFree
Method of screening for therapeutics for infectious diseases does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of screening for therapeutics for infectious diseases, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of screening for therapeutics for infectious diseases will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3684867